Abstract 1195P
Background
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant condition, caused by an alteration in the TP53 gene. Individuals with LFS are susceptible to developing a wide range of malignancies. National and international guidelines recommend annual WB-MRI scan for screening for cancer; however, WB-MRI is not yet implemented in this setting worldwide or in the UK. SIGNIFIED is a cost-effectiveness and implementation project that will assess the value of screening WB-MRI in LFS.
Methods
Individuals with LFS, with no cancer diagnosis in the past 5 years, were scanned using two WB-MRI, 12 months apart. Diffusion-weighted MRI images were acquired from vertex to feet. Incidental findings were further investigated and discussed in a specialist MDT meeting.
Results
Fifty-four asymptomatic individuals with LFS were recruited between May 2022 and July 2023 from Cancer Genetic Units across the United Kingdom. 40 females (74%) and 14 males (26%) were enrolled. The median age at recruitment was 42 years (range 18-70). Following 1st scan performed in 54 individuals, 16.6% of patients had a suspicious lesion that was biopsied/excised (N=9), and less than half (44%, N=4) had a confirmed cancer. Following 2nd scan performed in 44 individuals, 13.6% of patients had a suspicious lesion that was biopsied/excised (N=6) and in 83% of cases (N=5), a cancer diagnosis was confirmed. There was increased confidence in benignity when a comparator scan was available. In total, 9 cancers were detected and 66% (N=6) were diagnosed at stages 0-2 and underwent curative treatment. A further stage 3 pancreatic cancer (T4N0M0) was diagnosed and the patient received peri-operative chemotherapy and surgery with curative intent.
Conclusions
Overall, 9 cancers in 54 individuals were diagnosed with the help of WB-MRI. The rate of cancers detected in this cohort was higher than expected in a general population, consistent with the known risk of cancers in the LFS population. WB-MRI is a valuable and useful radiological tool for the detection of early cancers in LFS and our data support guidelines that it should be implemented as a regular screening test for this population. A health economics analysis is currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Small Business Research Initiative (SBRI) Healthcare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
212P - BRGSF-HIS mice as a predictive tool for safety assessment of biologics
Presenter: Kader Thiam
Session: Poster session 09
213P - Constructing a high-definition patient-digital twin (PDT) in treatment-naïve women with advanced cancer
Presenter: Leonardo Garma
Session: Poster session 09
215P - Detection of MUTYH for the prognosis and chemotherapy responsiveness of patients with non-small cell lung cancer
Presenter: Chi Wai Wong
Session: Poster session 09
216P - β-catenin is a potential prognostic biomarker in uterine sarcoma
Presenter: Ying Cai
Session: Poster session 09
218P - Exploiting a unique glycosaminoglycan for novel pan-cancer therapies and diagnostics
Presenter: Mette Agerbæk
Session: Poster session 09
219P - The landscape and prognostic impact of germline HLA-A subtypes in patients with advanced solid cancers
Presenter: Kyrillus Shohdy
Session: Poster session 09
220P - The role of fucosyltransferase 1 (FUT1) in CRC as a putative prognostic and predictive biomarker
Presenter: Lorenz Pammer
Session: Poster session 09
221P - ANGPTL4's role in cancer: A meta analysis and bioinformatics exploration
Presenter: Osama Younis
Session: Poster session 09
222P - Artificial intelligence (AI) based prognostication from baseline computed tomography (CT) scans in a phase III advanced non-small cell lung cancer (aNSCLC) trial
Presenter: Omar Khan
Session: Poster session 09